Health
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity – NewsMaker
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity
Vancouver, BC, Nov 2, 2020 – (ACN Newswire) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2,…
-
Noosa News23 hours agoQueensland weather forecast sees sunny weather for last week of winter
-
Business21 hours agoWhy the Betashares Nasdaq 100 ETF could be a perfect buy and hold pick
-
General17 hours agoMigrants raise concerns over Australia’s English tests for visa applicants
-
General23 hours agoEnergy provider ENGIE to ‘correct’ electricity bills for thousands of South Australian customers